Repligen (NASDAQ:RGEN) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday, December 30th.
Several other research analysts have also recently issued reports on the company. Jefferies Group reissued a “hold” rating and issued a $40.00 price target on shares of Repligen in a research note on Thursday, September 14th. CL King initiated coverage on Repligen in a research note on Monday, November 13th. They issued a “buy” rating and a $41.00 price target for the company. Citigroup initiated coverage on Repligen in a research note on Friday, December 8th. They set a “buy” rating and a $45.00 target price for the company. Zacks Investment Research raised Repligen from a “hold” rating to a “buy” rating and set a $43.00 target price for the company in a research note on Thursday, October 5th. Finally, JPMorgan Chase & Co. initiated coverage on Repligen in a research note on Tuesday, December 5th. They set an “overweight” rating and a $42.00 target price for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. Repligen has a consensus rating of “Buy” and a consensus price target of $44.38.
Repligen (RGEN) traded up $0.51 during trading hours on Friday, hitting $36.29. The stock had a trading volume of 283,994 shares, compared to its average volume of 213,714. Repligen has a 12 month low of $28.48 and a 12 month high of $46.81. The company has a market capitalization of $1,550.00, a PE ratio of 61.51, a price-to-earnings-growth ratio of 2.01 and a beta of 1.04.
Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.11 by $0.04. Repligen had a return on equity of 7.57% and a net margin of 16.93%. The company had revenue of $36.58 million during the quarter, compared to analysts’ expectations of $35.69 million. During the same quarter in the prior year, the business posted $0.08 earnings per share. The company’s revenue for the quarter was up 48.2% compared to the same quarter last year. research analysts expect that Repligen will post 0.61 earnings per share for the current fiscal year.
In related news, VP Howard Benjamin sold 12,729 shares of the firm’s stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $35.34, for a total transaction of $449,842.86. Following the completion of the transaction, the vice president now owns 36,554 shares of the company’s stock, valued at $1,291,818.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.50% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. lifted its holdings in shares of Repligen by 3.7% during the second quarter. BlackRock Inc. now owns 4,834,853 shares of the biotechnology company’s stock valued at $200,355,000 after purchasing an additional 170,551 shares during the last quarter. TimesSquare Capital Management LLC lifted its holdings in shares of Repligen by 19.8% during the second quarter. TimesSquare Capital Management LLC now owns 2,361,270 shares of the biotechnology company’s stock valued at $97,851,000 after purchasing an additional 390,545 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Repligen by 9.7% during the second quarter. Vanguard Group Inc. now owns 1,984,393 shares of the biotechnology company’s stock valued at $82,233,000 after purchasing an additional 175,191 shares during the last quarter. Conestoga Capital Advisors LLC lifted its holdings in shares of Repligen by 14.9% during the fourth quarter. Conestoga Capital Advisors LLC now owns 1,669,562 shares of the biotechnology company’s stock valued at $60,572,000 after purchasing an additional 216,330 shares during the last quarter. Finally, FMR LLC lifted its holdings in shares of Repligen by 6.2% during the second quarter. FMR LLC now owns 1,334,090 shares of the biotechnology company’s stock valued at $55,285,000 after purchasing an additional 78,060 shares during the last quarter. 82.48% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “BidaskClub Upgrades Repligen (NASDAQ:RGEN) to “Buy”” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/22/repligen-rgen-upgraded-to-buy-at-bidaskclub.html.
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.